Patents by Inventor Rika Nagao
Rika Nagao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120115851Abstract: An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R5 represents optionally substituted aryl or the like, Z represents —N?CHR6R7 or the like, R6 and R7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R101 and R102 together form ?O, and R103 and R104 represent H, or R101 and R104 together from a bond, and R102 and R103 together form a bond.Type: ApplicationFiled: January 18, 2012Publication date: May 10, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Nobuaki Eto, Rika Nagao, Tetsuko Kazama
-
Patent number: 8134015Abstract: An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and ?represents a single bond or a double bond, R5 represents optionally substituted aryl or the like, Z represents —N?CHR6R7 or the like, R6 and R7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R101 and R102 together form ?O, and R103 and R104 represent H, or R101 and R104 together from a bond, and R102 and R103 together form a bond.Type: GrantFiled: March 29, 2004Date of Patent: March 13, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Eto, Rika Nagao, Tetsuko Kazama
-
Patent number: 7816408Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.Type: GrantFiled: March 13, 2003Date of Patent: October 19, 2010Assignee: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Saki, Atsuya Takami, Rika Nagao
-
Publication number: 20090176993Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.Type: ApplicationFiled: March 13, 2003Publication date: July 9, 2009Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Patent number: 7211587Abstract: An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.Type: GrantFiled: June 7, 2004Date of Patent: May 1, 2007Assignee: Kirin Beer Kabushiki KaishaInventors: Kazuo Kubo, Teruyuki Sakai, Rika Nagao, Yasunari Fujiwara, Toshiyuki Isoe, Kazumasa Hasegawa
-
Publication number: 20060217426Abstract: An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R5 represents optionally substituted aryl or the like, Z represents —N?CHR6R7 or the like, R6 and R7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R101 and R102 together form ?O, and R103 and R104 represent H, or R101 and R104 together from a bond, and R102 and R103 together form a bond.Type: ApplicationFiled: March 29, 2004Publication date: September 28, 2006Applicant: Kirin Beer Kabushiki KaishaInventors: Nobuaki Eto, Rika Nagao, Tetsuko Kazama
-
Patent number: 6964975Abstract: The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula [1] or salts thereof: wherein R1 and R2 represents an optionally substituted alkyl group or the like; R3 represents a hydrogen atom or the like; R4 represent a group selected from the group consisting of (I) optionally substituted phenyl, aryl, or heterocycle, (II) substituted or nonsubstituted alkyl, and (III) substituted or nonsubstituted alkenyl, alternatively, R3 and R4 may form a ring structure together with a carbon atom to which they bind; and X represents an oxygen atom or a sulfur atom, provided that, when R3 is a hydrogen atom, R4 represents a group other than methyl, and the use thereof as a medicine.Type: GrantFiled: February 19, 2001Date of Patent: November 15, 2005Assignee: Kirin Beer Kabushiki KaishaInventors: Akihiro Ueno, Rika Nagao, Tomoko Watanabe, Hideo Ohta, Mikio Yagi
-
Patent number: 6939895Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.Type: GrantFiled: December 19, 2002Date of Patent: September 6, 2005Assignee: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Patent number: 6821987Abstract: An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.Type: GrantFiled: April 26, 2002Date of Patent: November 23, 2004Assignee: Kirin Beer Kabushiki KaishaInventors: Kazuo Kubo, Teruyuki Sakai, Rika Nagao, Yasunari Fujiwara, Toshiyuki Isoe, Kazumasa Hasegawa
-
Publication number: 20040229876Abstract: An object of the present invention is to provide compounds having potent antitumor activity.Type: ApplicationFiled: June 7, 2004Publication date: November 18, 2004Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Kazuo Kubo, Teruyuki Sakai, Rika Nagao, Yasunari Fujiwara, Toshiyuki Isoe, Kazumasa Hasegawa
-
Patent number: 6750255Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.Type: GrantFiled: January 17, 2002Date of Patent: June 15, 2004Assignees: NPS Pharmaceuticals, Inc., Kirin Beer KabushikiInventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Publication number: 20030176485Abstract: A novel calcium receptor active compound having the formula is provided:Type: ApplicationFiled: November 21, 2002Publication date: September 18, 2003Applicant: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Publication number: 20030144526Abstract: A novel calcium receptor active compound having the formula is provided:Type: ApplicationFiled: December 19, 2002Publication date: July 31, 2003Applicant: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Publication number: 20030114505Abstract: The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula [1] or salts thereof: 1Type: ApplicationFiled: August 19, 2002Publication date: June 19, 2003Inventors: Akihiro Ueno, Rika Nagao, Tomoko Watanabe, Hideo Ohta, Mikio Yagi
-
Publication number: 20030087907Abstract: An object of the present invention is to provide compounds having potent antitumor activity.Type: ApplicationFiled: April 26, 2002Publication date: May 8, 2003Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Kazuo Kubo, Teruyuki Sakai, Rika Nagao, Yasunari Fujiwara, Toshiyuki Isoe, Kazumasa Hasegawa
-
Publication number: 20020107406Abstract: A novel calcium receptor active compound having the formula is provided:Type: ApplicationFiled: January 17, 2002Publication date: August 8, 2002Applicant: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
-
Patent number: 6362231Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]P—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.Type: GrantFiled: June 6, 1999Date of Patent: March 26, 2002Assignee: NPS Pharmaceuticals, Inc.Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao